Last Price
37.32
Today's Change
-1.72 (4.40%)
Day's Change
37.18 - 39.40
Trading Volume
286,351
Market Cap
2 Billion
Shares Outstanding
64 Million
Avg Volume
480,158
Avg Price (50 Days)
42.10
Avg Price (200 Days)
41.67
PE Ratio
-15.95
EPS
-2.34
Earnings Announcement
20-Feb-2025
Previous Close
39.04
Open
38.90
Day's Range
37.1875 - 39.4
Year Range
29.24 - 53.27
Trading Volume
300,739
1 Day Change
-4.41%
5 Day Change
-8.35%
1 Month Change
-8.80%
3 Month Change
-25.15%
6 Month Change
-7.42%
Ytd Change
-8.73%
1 Year Change
10.45%
3 Year Change
-9.11%
5 Year Change
12.21%
10 Year Change
12.21%
Max Change
12.21%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.